Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Allurion Technologies and Compute Health Acquisition Corp (NYSE: CPUH) have entered into a business combination agreement, positioning Allurion to become publicly listed as Allurion Technologies, Inc. This innovative company is focused on obesity treatment, featuring the Allurion Gastric Balloon, a swallowable gastric balloon that allows for procedure-less weight loss. Since its inception, Allurion has treated over 100,000 patients worldwide, achieving an average weight loss of 30 pounds. Revenue has surged from $20 million in 2020 to $64 million in 2022. The transaction includes significant investments from RTW Investments and other notable figures.
Establishment Labs (NASDAQ: ESTA) announced preliminary unaudited revenue results for Q4 and FY 2022, projecting Q4 revenue between $43.3 million and $44.3 million, up 23% to 25% year-over-year, and FY 2022 revenue in the range of $161.2 million to $162.2 million, reflecting 27% to 28% growth. Constant currency growth for Q4 is projected at 27% to 29%, and for FY 2022 at 31% to 32%. The company cites strong growth and plans for the expansion of Motiva Implants and the rollout of Mia Femtech™ as key growth drivers.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a strategic partnership with Seishin Plastic and Aesthetic Surgery Clinic in Japan, launching Mia Femtech, a minimally invasive breast aesthetics procedure. This collaboration aims to address dissatisfaction among Japanese women regarding breast aesthetic options, potentially expanding the market significantly. The Mia procedure can enhance breast shape by 1 to 2 cup sizes in just 15 minutes, without general anesthesia. While currently not approved for commercial distribution in the U.S., this launch represents the first of many anticipated in 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12 at 7:30 a.m. Pacific Time. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women’s health technology, focusing on breast aesthetics and reconstruction, and has delivered over 2.5 million Motiva Implants® globally since 2010.
Establishment Labs Holdings (NASDAQ: ESTA) recently announced the approval of Motiva Implants® and the Motiva Flora® tissue expander for use in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA). These products have also secured reimbursement under the Japanese National Health System for post-mastectomy reconstruction. The first patient was treated successfully in November at Nagoya University Hospital. This launch signifies a commitment to enhancing women's health through innovative products backed by clinical data.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported third quarter 2022 sales of $38.2 million, a year-over-year increase of 31.7%. Revenue guidance for 2022 has been narrowed to $158 million to $162 million, reflecting 25% to 28% growth from 2021, with foreign exchange effects expected to reduce revenue by $6.5 million. Gross profit margin improved to 68.1%, while operating expenses rose 27.5% to $36.6 million. The company holds a cash balance of $65.3 million as of September 30, 2022, and plans to commercialize Mia Femtech™ and seek FDA approval for Motiva Implants in early 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Jefferies London Healthcare Conference and the Stephens Annual Investment Conference, both taking place from November 15-17, 2022. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Jefferies conference on November 15 at 5:00 PM GMT, while Denhoy will speak at the Stephens conference on November 17 at 11:00 AM CT. Live webcasts and archived versions of the presentations will be available on the company's investor relations website.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2022 on November 7, 2022, after market close. A conference call will be held at 4:30 pm ET to discuss these results. The company specializes in breast aesthetics and reconstruction, offering advanced silicone gel-filled implants, Motiva Implants®, with over 2 million implants distributed in over 80 countries since 2010. The company aims to continue improving women's health through innovative products.
Holzer & Holzer, LLC is investigating Establishment Labs Holdings Inc. (NASDAQ:ESTA) for potential compliance failures with federal securities laws. Following a report by Hindenburg Research, which alleged undisclosed conflicts of interest in key safety studies of Establishment Labs' breast implants, the company's stock price experienced a decline. The report claims significant pushback was received by a surgeon for publishing higher complication rates than those reported by the company. Shareholders who incurred losses are encouraged to contact Holzer & Holzer for potential legal recourse.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.